The genetic architecture and pharmacogenetic landscape of Charcot-Marie-tooth disease type 1 A: a narrative review toward precision molecular therapeutics
Current evidence on the genetic, molecular, and regulatory architecture of CMT1A is synthesized, with particular emphasis on distal regulatory elements controlling PMP22 expression, promoter-specific transcriptional regulation, and mechanisms contributing to phenotypic heterogeneity, support an increasingly individuali...